Previous 10 | Next 10 |
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease PR Newswire Acquisition to expand Lilly's immunology pipeline with oral integrin therapies INDIANAPOLIS and WALTHAM, Mass. , July 8, 2024 /PRNewswire/ -- Eli Lil...
2024-07-07 10:15:00 ET Summary Don’t fear recessions; embrace them with a well-constructed portfolio. Market prices and business fundamentals are distinct elements. Focus on the latter. We discuss two picks from non-discretionary sectors — telecom and healthcare....
2024-07-07 09:00:00 ET Summary BlackRock Health Sciences Trust is a healthcare sector-specific closed-end fund that invests in a fairly diversified portfolio of common stocks in the healthcare sector. It currently provides a reasonable yield of 6.3% plus an attractive discount of ...
2024-07-06 14:00:00 ET More on Eli Lilly, Novo Nordisk Novo Nordisk: Buy On Dips Eli Lilly Advances Alzheimer's Solutions With Kisunla Approval 5 Reasons Eli Lilly Just Keeps Rising Lilly's new Alzheimer's drug could generate $7.1B in sales: analyst N...
2024-07-06 08:31:00 ET Summary Amgen investors have outperformed the S&P 500 easily since my last Buy rating in late 2021. AMGN stock has benefited from the obesity drug euphoria as AMGN's MariTide enters Phase III studies. Novo Nordisk and Eli Lilly are GLP-1 leaders and ...
2024-07-05 15:04:46 ET More on Novo Nordisk Novo Nordisk: Buy On Dips Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk’s Ozempic, Wegovy linked to eye diso...
2024-07-05 06:22:00 ET Eli Lilly (NYSE: LLY) has become a big name in the anti-obesity market with the recent approval of Zepbound, which is likely to rake in billions in revenue alongside Mounjaro, the company's diabetes treatment. Year to date, the stock is already up 57% as inves...
2024-07-05 01:42:52 ET Summary Amgen shares have outperformed IBB by over 40% in the past year, driven higher by a major surge post-earnings in May. With a current price-to-earnings multiple in the mid-teens, I assert that solid and consistent EPS growth ahead warrants a higher va...
2024-07-04 12:45:03 ET Summary Novo Nordisk's Ozempic continues gaining popularity in weight management and diabetes markets, along with Wegovy, raising the question of whether the same can be hoped for the stock. There's a lot to like about the company. It's seeing robust sales g...
2024-07-04 11:30:00 ET Summary This article will present an in-depth analysis of drugs being developed to combat obesity and related diseases. Pharmaceutical companies are highly interested in the global obesity treatment market, which is expected to exceed $100 billion by 2030. ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 07:15:00 ET According to some research, bull markets tend to last an average of 2.6 years. The one we are currently experiencing has been going on for almost two years -- maybe it will soon end, maybe it won't. Equities that can perform well throughout bull runs might be good to ...
2024-07-26 07:45:00 ET Over the last 18 months, the stock market has been incredibly generous to investors. Since January 2023, the S&P 500 has soared 45%, while the tech-heavy Nasdaq Composite has rocketed by 72%. Outside of the technology industry, investors have also foun...
2024-07-25 19:06:06 ET It wasn't so long ago when Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks were flying high thanks to their hotly popular weight loss drugs (Wegovy/Ozempic for Novo Nordisk and Zepbound/Mounjaro for Lilly). In the pharmaceutical industry,...